STOCK TITAN

Amended Schedule 13G: Solas Capital and F. Golden Hold No Mural Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Mural Oncology plc received an amended Schedule 13G filing from Solas Capital Management, LLC and Frederick Tucker Golden reporting that neither the adviser nor Mr. Golden beneficially own any ordinary shares of the company. The filing lists the issuer's Dublin address and the security CUSIP G63365103. Both reporting parties state 0 shares owned and 0.0% of the class, and clarify the adviser relationship to private funds while noting the funds disclaim beneficial ownership. Signatures by Frederick Tucker Golden certify the accuracy of the statement.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Reporting parties declare no beneficial ownership; filing is a routine disclosure with no material stake.

The Schedule 13G/A indicates Solas Capital Management, LLC (an investment adviser) and its portfolio manager, Frederick Tucker Golden, report zero beneficial ownership of Mural Oncology ordinary shares and 0.0% of the class. The filing documents the adviser relationship to private funds and includes the standard disclaimer that the funds disavow beneficial ownership. For investors, this filing does not signal accumulation, divestiture, or change in control and appears informational and routine.

TL;DR: Compliance filing meets disclosure requirements; no governance or control implications due to zero ownership.

The amendment fulfills Rule 13d reporting obligations by identifying the reporting persons, their addresses, citizenships, and voting/dispositive powers, all reported as zero. The explicit statement that the adviser manages funds but that those funds disclaim beneficial ownership is standard legal protection under Rule 13d-4. There are no indications of group formation, subsidiary acquisition, or other governance actions affecting Mural Oncology.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Solas Capital Management, LLC
Signature:/s/ Frederick Tucker Golden
Name/Title:Frederick Tucker Golden/General Partner, Solas Capital Holdings, LP, its Member
Date:08/14/2025
FREDERICK TUCKER GOLDEN
Signature:/s/ Frederick Tucker Golden
Name/Title:Frederick Tucker Golden
Date:08/14/2025

FAQ

Who filed the Schedule 13G/A for MURA?

Solas Capital Management, LLC and Frederick Tucker Golden filed the amended Schedule 13G.

How many Mural Oncology (MURA) shares do the filers beneficially own?

0 shares; both Solas Capital Management and Frederick Tucker Golden report 0.0% ownership.

What CUSIP and class of security does the filing reference?

The filing references ordinary shares, nominal value $0.01 per share, CUSIP G63365103.

Does the filing indicate any change in control or group ownership?

No. The filing reports zero ownership, states no group membership, and notes the funds disclaim beneficial ownership.

When was the Schedule 13G/A signed?

Signatures by Frederick Tucker Golden are dated 08/14/2025.
Mural Oncology PLC

NASDAQ:MURA

MURA Rankings

MURA Latest News

MURA Latest SEC Filings

MURA Stock Data

35.38M
14.43M
13.03%
57.62%
3.51%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2